Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

"1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered."